TrialClinical ophthalmology (Auckland, N.Z.)2024
An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients.
Nobuhiro Goi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.